BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32716687)

  • 1. Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies.
    Park KJ; Choi SH; Lee JS; Kim JK; Kim MH; Jeong IG
    J Urol; 2020 Dec; 204(6):1141-1149. PubMed ID: 32716687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
    J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy.
    Kinnaird A; Sharma V; Chuang R; Priester A; Tran E; Barsa DE; Delfin M; Kwan L; Sisk A; Felker E; Marks LS
    J Urol; 2020 Dec; 204(6):1180-1186. PubMed ID: 32614257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    Song G; Ruan M; Wang H; Fan Y; He Q; Lin Z; Li X; Li P; Wang X; He Z; Zhou L
    J Urol; 2020 Dec; 204(6):1202-1208. PubMed ID: 32716686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy.
    Kenigsberg AP; Renson A; Rosenkrantz AB; Huang R; Wysock JS; Taneja SS; Bjurlin MA
    Eur Urol Oncol; 2018 Oct; 1(5):418-425. PubMed ID: 31158081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis.
    Goldberg H; Ahmad AE; Chandrasekar T; Klotz L; Emberton M; Haider MA; Taneja SS; Arora K; Fleshner N; Finelli A; Perlis N; Tyson MD; Klaassen Z; Wallis CJD
    J Urol; 2020 Jun; 203(6):1085-1093. PubMed ID: 31609177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography-fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3-5.
    Hakozaki Y; Matsushima H; Murata T; Masuda T; Hirai Y; Oda M; Kawauchi N; Yokoyama M; Kume H
    Int J Urol; 2019 Feb; 26(2):217-222. PubMed ID: 30461076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.
    Hamoen EHJ; de Rooij M; Witjes JA; Barentsz JO; Rovers MM
    Eur Urol; 2015 Jun; 67(6):1112-1121. PubMed ID: 25466942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of PI-RADS Category 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and meta-analysis.
    Wadera A; Alabousi M; Pozdnyakov A; Kashif Al-Ghita M; Jafri A; McInnes MD; Schieda N; van der Pol CB; Salameh JP; Samoilov L; Gusenbauer K; Alabousi A
    Br J Radiol; 2021 Feb; 94(1118):20191050. PubMed ID: 33002371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years.
    Meng X; Rosenkrantz AB; Huang R; Deng FM; Wysock JS; Bjurlin MA; Huang WC; Lepor H; Taneja SS
    J Urol; 2018 Nov; 200(5):1022-1029. PubMed ID: 29886090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of diagnostic performance between two prostate imaging reporting and data system versions: A systematic review.
    Li W; Xin C; Zhang L; Dong A; Xu H; Wu Y
    Eur J Radiol; 2019 May; 114():111-119. PubMed ID: 31005160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.